Curaleaf Holdings (CURA) completed a 1-for-3 reverse stock split on Friday, June 5, 2026, a move that lifted its Toronto Stock Exchange share price to C$15.88 by mid-morning trading. The consolidation, which reduces the company's outstanding subordinate voting shares from approximately 698.7 million to 232.9 million, is aimed at satisfying the minimum price requirements for a potential uplisting to a major U.S. exchange.
The reverse split does not alter Curaleaf's overall market value but is a strategic step to make the stock more attractive to institutional investors and meet the listing standards of U.S. exchanges. The stock traded in a range of C$14.73 to C$16.00 on Friday, according to Investing.com data.
Trulieve's NYSE Listing Sets Competitive Tone
Curaleaf's action comes on the heels of a significant milestone by rival Trulieve Cannabis, which announced that its subordinate voting shares will begin trading on the New York Stock Exchange (NYSE) on June 10 under the ticker "TRLV." Trulieve CEO Kim Rivers hailed the listing as a "major advancement for Trulieve and the industry," signaling a competitive push among major cannabis operators for U.S. exchange access.
While Curaleaf has not yet secured approval for a U.S. listing, Chairman and CEO Boris Jordan described the reverse split as part of the company's "long-term effort" to achieve that goal. The company also cited the need to comply with minimum price thresholds set by some retail brokerages and to enhance accessibility for institutional investors.
Cannabis Sector Gains Amid Broader Market Weakness
The cannabis sector saw notable gains on Friday, even as the broader market faced headwinds. The S&P/TSX Composite Index in Canada fell 0.7% following disappointing jobs data, which reignited concerns about interest rates. In contrast, the AdvisorShares Pure U.S. Cannabis ETF (MSOS) rose 6.3% to $5.42, and Tilray Brands (TLRY) added 2.1% to $5.30. Other U.S. cannabis operators, including Green Thumb Industries (GTBIF) and Trulieve's OTC shares, also moved higher.
Regulatory Landscape and Earnings Context
The regulatory environment continues to shape investor sentiment. In April, U.S. regulators reclassified FDA-approved and state-licensed medical marijuana to Schedule III, a less restrictive category. This change has implications for Section 280E of the tax code, which prevents businesses from deducting expenses related to Schedule I or II substances. However, Reuters reported that the reclassification was narrower than some investors had anticipated, leading to mixed reactions. CB1 Capital's Todd Harrison noted that the process "confused some people," while AdvisorShares' Dan Ahrens described some of the subsequent price action as a "sell the news" event.
Curaleaf enters this period with improved financials. The company reported first-quarter revenue of $324.2 million, a 6% year-over-year increase. Net income from continuing operations reached $70.1 million, and adjusted EBITDA—a measure that excludes interest, taxes, depreciation, amortization, and other items—stood at $63.4 million. These results mark a stronger earnings profile compared to previous quarters.
Outlook and Market Implications
Despite the reverse split, Curaleaf has not yet announced approval for a U.S. exchange listing, leaving the next chapter of its uplisting story unwritten. The cannabis sector continues to grapple with regulatory hurdles, thin trading in some over-the-counter stocks, and the ongoing gap between medical marijuana relief and the smaller adult-use market. Investors are now watching to see if Curaleaf can clear the same listing hurdle that Trulieve has successfully navigated.
The reverse split effectively raises the per-share price, shifting the focus from mathematical adjustments to market access. As the cannabis industry evolves, Curaleaf's ability to secure a U.S. listing could be a pivotal factor in its competitive positioning and investor appeal.
